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1. Introduction 
Understanding how signal inputs and outputs are organised in membrane protein 
signalling networks is an important question in biology. The current goal is to derive 
methods that would allow the 'watching' of these network proteins in action and at atomic 
resolution to see details of their structure. This requires the addition of a 'time' dimension to 
structural biology so that the spatio-temporal parameters of all atoms in each protein can be 
described in detail. This is a huge challenge that in cell-free systems has begun to be 
partially addressed through dynamic experiments combined with molecular simulations. 
However, in cells, the functions of particular structural motifs are not just constrained by 
Brownian motions, energy landscapes and thermodynamics, but also by the local 
availability of partners in subcellular compartments and the boundary constraints imposed 
by cell environments, for example in the plasma membrane, with its 2D dimensionality, 
local curvature and electric fields. To understand protein function in cells, observations have 
to be made in the only physiologically-relevant 'laboratory', the cell. This adds levels of 
complexity to an already vast challenge.  
Using molecular biology techniques in combination with optical methods, we can now 
annotate individual genes and gene products, screen for protein-protein, protein-DNA and 
small molecule interactions, and quantify dynamic changes. However, only the combination 
of fluorescence imaging, fluorescence resonance energy transfer (FRET) and single molecule 
detection currently offers sensitive spatio-temporal detection in cells for low abundance 
protein interactions. This is beginning to bridge the gap between protein structure and 
function by allowing real-time quantitative observations of structural details, 
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conformational intermediates, association and dissociation constants, diffusion rates, and 
rare events. Previous information on complex protein networks, such as the human 
epithelial growth factor receptor (HER) bio-system, has been derived generally from high-
throughput screens and/or single cell models using ensemble (averaged) technologies such 
as biochemical extraction followed by mass spectrometric analysis. Here we describe 
examples of how single molecule and ensemble fluorescence microscopy methods can offer 
the means to understand and predict in cells the structure-function relationships of proteins 
in the input layer of the HER signalling network, from the changes in complex interactions 
between their microscopic molecular components to their response to perturbations. 
2. The human epidermal growth factor receptor (HER) family  
HER molecules are prototypical examples of the growth factor receptor tyrosine kinase 
(RTK) super-family, which also comprises 18 sub-groups of cell surface receptors for many 
growth factors, cytokines and hormones (Schlessinger 2000). The HER family consists of 
four homologous receptors, known in cells of human origin as HER1, HER2, HER3 and 
HER4 (Citri & Yarden 2006). The HER1 molecule (also known as Epidermal Growth Factor 
Receptor (EGFR)) is the founding member of the RTK family (Fig. 1). In other mammals 
HER molecules are known as ErbB receptors (ErbB1-4). This name originates from an 
oncogenic erythroblastosis retrovirus (v-erbB) which encodes a mutated homologue of 
HER1 (Downward et al. 1984).  
HER molecules are encoded as single pass trans-membrane proteins (Fig. 1). The primary 
structure of HER1, which is shared with all receptor tyrosine kinases, consists of a single 
polypeptide chain (1,186 amino acids) of 170 kD, containing a heavily glycosylated 622-
amino acid residue amino-terminal extracellular ligand binding domain that is connected to 
the cytoplasmic domain by a single transmembrane (TM) helix of 23 residues. The 542-
residue cytoplasmic domain contains a conserved 250-amino acid tyrosine kinase core 
(Ullrich et al. 1984). The kinase domain is the locus of the enzymatic activity of the receptor 
and at the core of its signalling function in the cell. 
Mature HER molecules are translocated to the plasma membrane lipid bilayer, which is the 
outer boundary of the cell separating the extracellular and intracellular environments 
(Hillier & Hoffman 1953), were they are able to accept signalling cues from their 
environment (Fig. 1). In the HER family signalling cues are provided by 13 potential ligands 
(reviewed in Yarden & Sliwkowski 2001; Citri et al. 2003; Citri & Yarden 2006). These 
ligands, known as epidermal growth factor (EGF)-related peptides, can be classified in three 
functional groups according to their specific binding targets (Olayioye et al. 2000): EGF, 
transforming growth factor alpha (TGF), amphiregulin and epigen bind HER1; 
betacellulin, epiregulin and heparin binding EGF-like growth factor bind HER1 and HER4; 
neuregulins 1 to 4 (NRG, also known as heregulins), bind either both HER3 and HER4 
(NRG-1 and NRG-2) or HER4 alone (NRG-3 and NRG-4). HER2 is thought to be an orphan 
receptor, with none of the EGF family of ligands discovered so far being able to bind and 
activate it (Baselga & Swain 2009; Olayioye et al. 2000).  
EGF-related peptide growth factors are synthesised as cell membrane associated precursors 
in the plasma membrane. The extracellular domains of membrane-bound growth factors are 
subsequently shed via the action of members of a family of proteases known as a disintegrin  
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Fig. 1. A cartoon of a 2:2 EGF/HER1 dimer complex showing the initial stages of effector 
recruitment and signalling. Shown are the external domains of HER1 bound to EGF (black 
spheres) derived from crystallographic data (Garret et al. 2002; Ogiso et al. 2002; Ferguson et 
al. 2003). In the cytoplasm the two tyrosine kinase domains of the HER1 dimer form an 
asymmetric dimer (Zhang et al. 2006). Following recruitment and phosphorylation of 
effectors like Grb2, recruitment of Sos leads to the activation of Ras via exchange of GTP for 
GDP to activate the Ras mediated signalling pathway (Zhang & Liu 2002). 
and metalloproteases (ADAMs) family. As indicated by their name, these proteolytic 
enzymes are zinc-dependent trans-membrane metalloproteases (Zhou et al. 2005). Other 
members of the ADAMs family also shed extracellular domains of other cytokines and 
receptors (Edwards et al. 2008). Growth factor shedding is critical for the production of 
soluble functional HER ligands that can activate cell signalling via paracrine and autocrine 
mechanisms. Growth factors that remain membrane-bound can bind HER molecules on 
adjacent cells leading to juxtacrine signalling (Riese & Stern 1998). 
3. Ligand-induced receptor dimerisation 
An essential step in HER activation and signalling is achieved via ligand-induced receptor 
dimerisation (Schlessinger 2000). Ligand molecules bind the extracellular region of their 
cognate receptor in specific sites promoting dimerisation and interactions between two 
receptor monomers (Fig. 1). If two receptors are of the same type (e.g. HER1-HER1 dimer) 
the process is known as homo-dimerisation. For receptors of two different types (e.g. HER1-
HER3) the process is known as hetero-dimerisation. Inactive receptors are believed to exist 
mainly as monomers, although unliganded (inactive) HER dimers have also been detected 
in cells (Martin-Fernandez et al. 2002; Clayton et al. 2005).  
A defining characteristic of the HER family is that only HER1 and HER4 can bind ligands 
and also signal autonomously via homo-dimerisation and trans-activation of their tyrosine 
kinases (Yarden & Sliwkowski, 2001). In contrast, HER2 and HER3 are not autonomous. As 
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discussed above, HER2 lacks the intrinsic ability to interact with known ligands, whereas 
the kinase of HER3 is defective (reviewed in Citri et al. 2003). HER2 and HER3 can therefore 
only initiate signals through hetero-dimer formation. The following interacting pairs have 
been reported in the literature: HER1-HER1, HER4-HER4, HER1-HER2, HER1-HER3, HER1-
HER4, HER2-HER3, HER2-HER4 and HER3-HER4 (reviewed in (Bublil & Yarden 2007)). 
HER2-HER2 and HER3-HER3 homo-dimers may also exist, but this is less certain. Despite 
having no soluble ligand, HER2 is important because it is the preferred hetero-dimerisation 
partner of the other ligand-bound family members (GrausPorta et al. 1997). In addition, 
there are also reports of higher order homo-oligomers of HER1 (such as tetramers) (Clayton, 
et al. 2005; Clayton et al. 2008).  
4. HER signalling in cancer 
Aberrant behaviour of HER family members has been implicated in many cancers (Sharma 
et al. 2007). Research has shown that in adulthood, excessive HER signalling upsets the 
balance between cell growth and apoptosis resulting in the development of a wide variety of 
solid tumours (reviewed in Bublil & Yarden 2007). In particular, the level of expression 
and/or activation of HER1 and HER2 are altered in many tumours of epithelial origin, and 
clinical studies indicate that HER1 and HER2 have important roles in tumour aetiology and 
progression (Hynes & Lane 2005). For example, deregulated signalling by cell surface HER1 
receptors (e.g. via activating mutations in the HER1 gene) is implicated in a substantial 
percentage of lung cancers (Paez et al. 2004). Gene amplification leading to HER1 
overexpression is also often found in other human cancers like glioblastoma and esophageal 
squamous cell carcinoma (Ohgaki et al. 2004; Sunpaweravong et al. 2005). As activation of 
HER molecules has been shown to result in the growth and progression of the malignancy, 
the HER family is an important target of the pharmaceutical industry and there have been 
considerable research efforts directed toward the development of effective inhibitors of HER 
signalling. Two important types of HER inhibitor are in clinical use: Humanized antibodies 
directed against the extracellular domain of HER1 or HER2, which elicit an immune 
response and/or block ligand-binding and dimerisation, and small-molecule tyrosine-kinase 
inhibitors (TKIs) that compete with ATP in the tyrosine-kinase domain of the receptor 
inhibiting its intrinsic tyrosine kinase activity (Hynes & Lane 2005). Some of these TKIs have 
already demonstrated substantial clinical activity against several cancers (e.g. targeting of 
HER1 and HER2 are in different stages of pre-clinical and clinical trials) (Bublil & Yarden 
2007; Citri & Yarden 2006; Hynes & Lane 2005). 
5. Structural insights on the HER family: The extracellular domain 
The original paradigm proposed for the activation of HER molecules was that the binding of 
ligand induced the dimerisation of monomeric unliganded receptors via ligand-crosslinking 
of two receptor moieties (Schlessinger 2000). Contrary to these expectations, crystallographic 
studies of HER1 ectodomain fragments bound to two types of ligands, EGF and TGF, have 
shown quasi-symmetric 2:2 ligand-receptor dimers where each ligand binds simultaneously 
to subdomains I and III of one of the monomers (Fig. 2). These HER1 dimer structures 
therefore clearly showed that the dimerisation of this receptor was not directly mediated by 
the binding of ligand but achieved exclusively via receptor-receptor contacts via subdomain 
II (Garrett et al. 2002; Ogiso et al. 2002) (Fig. 2).  
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Crystal structures of unliganded HER1, HER3 and HER4 monomers show that these are 
held in a closed conformation by an intramolecular tether formed by loops in subdomains II 
and IV (Bouyain et al. 2005; Ferguson et al. 2003; Hyun-Soo & Leahy 2002). These data 
suggest that ligand binding and dimerisation involves major extracellular structural 
rearrangements in HER1, HER3 and HER4 molecules because in ligand-occupied receptor 
dimers the intramolecular tether is broken and the receptor is opened into an extended 
conformation which interacts with another monomer to form a back-to-back dimer (Burgess 
et al. 2003; Ferguson, et al. 2003). Interestingly, unliganded HER2 has an extended 
configuration that resembles the structure of ligand-bound ‘activated’ HER1 (Cho et al. 
2003). This may explain the unique properties of HER2, which has no known ligand and can 
cause cell transformation (and tumorigenesis) by simple overexpression (Yu & Hung 2000). 
The latter appears to force the equilibrium towards spontaneous HER2 homodimer 
formation, which leads to receptor activation in the absence of ligands. This is the situation 
observed in a variety of human cancers. 
 
Fig. 2. A structural model of the 2:2 EGF/HER1 complex. Shown are the four subdomains 
(I–IV) of the HER1 ectodomain (Garret et al. 2002; Ogiso et al. 2002; Ferguson et al. 2003) and 
the TM helices. In the cytoplasm, the two tyrosine kinase domains form an asymmetric 
dimer (Zhang et al. 2006). The EGF ligands are shown in yellow. Fragments known from 
crystallography or NMR are coloured, while the pale grey sections denote regions of 
uncertain structure, including the extracellular JM linker, the intracellular JM domain (Jura 
et al. 2009a; Brewer et al. 2009), and the C-terminal tails. On the latter, purple spheres 
indicate known auto-phosphorylation sites. Figures have been prepared using visual 
molecular dynamics (Humphrey el al. 1996). 
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The typical high-resolution representation of ligand-bound HER1 dimeric holoreceptors is 
depicted in Fig. 2. This generally accepted model has been derived by putting together the 
available structural information on extracellular and intracellular fragments (Garrett et al. 
2002; Ogiso et al. 2002; Ferguson et al. 2003; Brewer et al. 2009; Jura et al. 2009a; Jura et al. 
2009b; Zhang et al. 2006). In this model, the extracellular domains are oriented with respect 
to the membrane based on the historical view that receptors are protruding from the plasma 
membrane as antennae.  
6. Structural insights into the HER family: The intracellular domain  
Ligand binding and the dimerisation of HER1 extracellular domain leads across the plasma 
membrane to the formation of an asymmetric dimer by the two associated intracellular 
kinases (Zhang et al. 2006) that is stabilised by the inner juxtamembrane (JM) region (Brewer 
et al. 2009; Jura et al. 2009a) (Fig. 2). Kinase activation follows through an allosteric 
mechanism in which the C-lobe of one kinase (activator) “pushes” the N-lobe of the other 
kinase (receiver) in an interaction that is highly reminiscent of the activation of CDK2 by 
binding of cyclin A (Jeffrey et al. 1995). Active kinases in the homodimer (and possibly 
heterodimer) then proceed to phosphorylate in trans tyrosine residues in the C-terminal tail 
of the partner receptor (Zhang et al. 2006). Fig. 2 depicts the C-termini of a HER1-HER1 
dimer (for which there is no structural data), showing the location of tyrosine amino acid 
residues. These tyrosine residues are phosphorylated by the addition of a phosphate group 
(PO43-). When phosphorylated these sites act as docking sites for a large repertoire of 
intracellular adaptors and enzymes containing Src homology 2 (SH2) domains (Pawson 
2004). These include Grb2 (Fig. 1), GAP, Shc (Pai & Tarnawski 1998), phospholipase 
C(PLC) (Katan 1998), and phosphatidylinositol 3’-kinase (PI3K) (Vanhaesebroeck et al. 
2001), which regulate Ras/Rho-like GTPases (Ridley 2001), Ca2+ second messenger 
production (Defize et al. 1989), and the Ras-activated MAP/SAP kinase pathways (Zhang & 
Liu 2002). In this way, HER molecules start the intracellular signalling cascades that lead to 
cell proliferation, changes in cell morphology, trafficking, and the termination of signals via 
endocytosis of the receptor-ligand complexes (Carpenter 2000; Sorkin 2001).  
The pattern of phosphorylated tyrosine motifs is specific to each HER homo and hetero pair 
(Schulze, Deng, & Mann 2005a). This is the way by which intracellular effector proteins can 
selectively be recruited by different HER pairs at the plasma membrane to initiate different 
signalling events and cascades in the cell (reviewed in (Citri & Yarden 2006)). The 
combinatorial variety of homo/hetero HER1-4 complexes therefore provides a mechanism 
by which different cell responses can be induced via recruitment of different combinations 
of signalling effectors to phosphorylated homo and hetero HER complexes, activating 
intracellular pathways for signal attenuation (receptor desensitisation, down-regulation, 
endocytosis and trafficking), signal amplification and cell growth, death signals (apoptosis) 
and other signal processing pathways (Yarden & Sliwkowski 2001). This may explain how 
subtle differences in the expression pattern of HER1-4 and their ligands may ultimately 
regulate development and homeostasis in many tissue types. 
7. Towards a systems biology perspective  
A glimpse of the true complexity in the HER network has only been obtained recently in the 
light of high-throughput screens and proteomic assays. These have added hundreds of 
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putatively assigned new interactions and several new signal regulators in different cellular 
compartments to an already complicated picture, making the network increasingly difficult 
to describe. The burgeoning of data is facilitating the emergence of a cellular systems level 
perspective (Jones et al. 2006; Schulze, Deng, & Mann 2005b) which is beginning to uncover 
non-intuitive features of HER signalling, such as the high biological potency of a low-
affinity mutant of EGF (Schoeberl et al. 2002). The emerging view is that of a complex ‘fail-
safe’ robust network system (Citri & Yarden 2006), which is able to maintain some degree of 
function through embedded layers of functional degeneracy, modularity, redundancy, 
buffering and signalling controls, even if some components are damaged. The robustness of 
the HER signalling network is underlined by its bi-stability (ligand-regulated ON/OFF 
states) and its ‘bow-tie’ configuration, in which multiple positive cues (ligand binding) and 
negative cues (receptor trafficking) are fanned out through an intermediate core processing 
unit. The core consists of multiple isoforms of interconnected effector units and signalling 
cascades, intertwined with densely coupled subnetworks (e.g. the phosphoinositide and 
Ca2+ networks and the endocytic machinery; see (Sorkin 2001)). The number of intracellular 
proteins that form part of this core is vast, including not only the HER1 effectors outlined 
above, but also entire families of adaptors and enzymes of (e.g. Grb2 and Shc) (Pai & 
Tarnawski 1998), ubiquitin ligases (e.g. the E3 ubiquitin ligase c-Cb) (reviewed (Thien & 
Langdon 2005)), lipid and protein kinases (e.g. PI3K, Akt; reviewed (Vanhaesebroeck, et al. 
2001)), GTPases (Ridley 2001) (e.g. Ras, Rho) and phospholipases (e.g. PLC-γ (Katan 1998)). 
More recently, the activation of the small RhoGTPase Cdc42 by HER1 signalling has also 
been established (El-Sibai et al. 2007; Feng et al. 2006; Kurokawa et al. 2004). HER signalling 
also results in the specific induction of outputs through transcription factors (Grandis et al. 
1998) (e.g. STAT3) which, depending on the exact combination recruited through the core 
and the cellular context, ultimately lead to different cell fates, including proliferation, 
survival, adhesion, migration and differentiation (Oda et al. 2005). 
8. Multi-colour labelling of signalling proteins in the HER network 
Because of the complexity of the HER signalling network (Oda, et al. 2005), the systems-level 
perspective provides a useful framework to describe network behaviour and to expose and 
predict the fragility of network activity centres. However, the bottleneck in mathematical 
‘Systems’ modelling is incomplete biological understanding. This is mainly due to the 
difficulties of obtaining quantitative kinetic/dynamic data and structure-function 
relationships in the cellular environment. To gain a better understanding of HER signalling 
that can facilitate a systems perspective it is necessary, for example, to devise better means 
of obtaining structural data on the input layer of the HER signalling network. It is also 
necessary to obtain much more information on the dynamic rules of engagement between 
HER network proteins in vivo and to understand the positive and negative feedback-loops 
regulating the HER network that allow functioning under perturbation.  
Fluorescence microscopy methods provide a convenient approach to study protein 
conformation and dynamic interactions between HER network members at the plasma 
membrane of living cells. This method is non-invasive and allows several types of proteins 
to be specifically tagged and observed simultaneously. For example, heteromeric pan-HER 
interactions can in principle be measured in living cells by using a combination of 
fluorophores to label each of the four members of the HER family with a different colour tag 
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(Fig. 3) and then employing FRET and/or multicolour single molecule tracking to follow 
their interactions in real-time (see below). These methods can in principle be extended in 
cells bio-engineered to express specific combinations of interacting fluorescent 
ligand/HER1-4/adaptor/inhibitor variants.  
 
Fig. 3. A cartoon showing the HER1 homo-dimer and hetero-dimers at the plasma 
membrane. (The intracellular domains of hetero-dimers are not shown for simplicity). 
Different colour labels are targeted to the extracellular domains (small colour spheres). 
Intracellular proteins can be labelled using fluorescence proteins such as GFP. 
One strategy to label HER molecules is to use their cognate ligands (e.g. EGF or small 
affibodies) as delivery vehicles for the fluorophores (Fig. 3). For this, fluorophores of 
different colours can be bound in a 1:1 ratio to different activating and non-activating 
ligands, each specific for one of the receptor types. Once these ligands bind their cognate 
receptors, each receptor type will be tagged with a different colour molecule. This means 
that each receptor type is colour-coded and will appear in a different colour channel. Other 
strategies include chemical synthesis of fluorescent ACP- (a 6 kDa, acyl carrier protein), 
MCP- (a mutant version of ACP), SNAP- and CLIP-tag substrates, fluorescence protein 
fusions to HER C-termini, N/C-termini of scaffolds and effectors (Fig. 2) and cell permeant 
benzylguanine (BG) or benzylcytosine (BC) dye derivatives (Banala, Arnold, & Johnsson 
2008), including BG and BC conjugated to TMRstar (which can fluorescently label any O6-
alkylguanine-DNA alkyltransferase (AGT)-tagged, i.e. SNAP or CLIP tagged, intracellular 
proteins in live cells).  
The remainder of this chapter shows steps taken in our laboratory towards the development 
of an integrated experimental approach that can provide data on multi-molecular 
interactions towards a system-focused approach. These steps have so far consisted of 
developing the tools to extract structural and dynamic information on the HER bio-system 
in the cellular context by gathering information on conformational changes, receptor 
interactions and the dynamic rules of engagement in HER signalling.  
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9. Investigating HER protein-protein interactions by FRET 
FRET is a phenomenon by which the excited-state energy of an optically excited fluorescent 
molecule (donor) is transferred to a neighbouring fluorescent molecule (acceptor) non-
radiatively via intermolecular Van der Waals (dipole-dipole) interactions (Stryer & 
Haugland 1967). For FRET to occur the electronic levels of donors and acceptors must 
overlap. FRET depends on the distance between donors and acceptors as the inverse of the 
sixth power and is therefore very sensitive to short inter-molecular distances in the range 
~2-8 nm. It can therefore be a useful tool to investigate molecular interactions.  
FRET observations can be made either in the steady-state, by detecting the quenching of the 
fluorescence emitted by the donor as energy is transferred to the acceptor, or time-resolved, 
by measuring the shortening of the fluorescence lifetime of the donor. FRET imaging 
between fluorescent EGF derivatives bound to HER1 molecules in cells has been widely 
employed to investigate HER1 homo-dimerisation (Gadella & Jovin 1995; Sako et al. 2000; 
Martin-Fernandez et al. 2002; Clayton et al. 2005; Clayton et al. 2008). A popular strategy for 
this was to measure the efficiency of FRET between donor and acceptor fluorophores bound 
to the N-termini of receptor-bound EGF ligands. Although distances shorter than ~8 nm 
(averaged over the receptor population) were ubiquitously reported by FRET in these 
conditions in cells, it should be noted that the preferred (back-to-back) crystallographic 
dimer shows N-terminal inter-ligand distances of >11 nm (Fig. 3). This distance is too large 
to be detected by FRET and will remain so even when extreme deformations are applied to 
this crystal structure; for example, by changing the angle between domains I and III and 
domain II and/or applying extreme perturbations along low frequency normal modes. The 
FRET results therefore suggest that other interfaces between receptor monomers not yet 
found by crystallographic methods must also occur at the plasma membrane of cells.  
 
Fig. 4. The back-to-back / head-to-head / back-to-back tetramer on the plasma membrane 
(Kästner et al. 2009). The grey- stick models are the atomistically modelled lipid molecules 
of the membrane. EGF ligands are shown in red. 
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Attempts to understand the origin of FRET between donor/acceptor EGF ligands bound to 
HER1 include the pioneering work by Clayton et al. in intact BaF/3 cells, a murine 
interleukin-3 dependent pro-B cell line which do not overexpress ErbB1 (the mammal HER1 
equivalent). Using fluorescence correlation microscopy, this work showed the presence in 
cells of tetramers of activated cell surface EGF/ErbB1 complexes. FRET in turn showed the 
presence of very short distances (< 4 nm) between ErbB1-bound EGF ligands (Clayton, et al. 
2005). It was postulated that these short distances could explain the presence of FRET in the 
context of a tetramer formed by two back-to-back crystallographic dimers. These short 
distances between EGF ligands bound to HER1 were subsequently found in human A431 
epithelial cells by single pair FRET imaging (Webb et al. 2008). This work provided 
additional evidence for HER1-HER1 interfaces in cells other than that described in the back-
to-back crystallographic structure.  
The work of Clayton et al. 2005 and Webb et al. 2008 set the basis for two new models of 
HER1 activation: In one model tetramers were generated through side-by-side contacts 
between two adjacent back-to-back dimers; however, there is no crystallographic evidence 
yet for this arrangement. In the second model (Fig. 4) tetramers were made of two back-to-
back dimers joined by a weak, asymmetric ‘‘head-to-head’’ interface seen in crystal 
structures (Garret et al. 2002). This interface also results in short distances between the N-
termini of the two bound EGF molecules of < 4 nm. Molecular dynamics (MD) simulations 
showed that the head-to-head interaction stabilises appreciably when the tetramer is relaxed 
on the membrane (its interface area increased from 443 Å2 seen in the crystal structure to 604 
Å2) (Kastner, et al. 2009). In this tetramer the two dimers remained stable but lost the 
approximate 2-fold symmetry of the crystal structure. The average dimerisation interface 
area rose from 1,197 Å2 to 1,483 Å2, largely as a result of additional interactions between the 
N-terminus and the dimerisation arm, while the two ligands buried 1,166 Å2 and 1,211 Å2 at 
distinct binding sites.  
Interestingly, the ligand-membrane distances predicted by the tetramer in Fig. 4 are 
significantly shorter than those predicted by the crystallographic back-to-back dimers 
standing upright from the membrane (Fig. 3), a hypothesis that can be tested using FRET 
(see section 11). Initial measurements by Webb et al. (2008) were consistent with the short 
ligand-membrane distances proposed by the model in Fig. 4 (see section 11). 
10. Investigating the origin of ligand – Binding heterogeneity to HER1  
Possibly the main disappointment of the HER crystal structures is that they did not explain 
a 30-year old puzzle in the HER signalling field, namely the origin of the characteristic 
heterogeneity in EGF-binding affinity to cell-surface HER1 molecules. This heterogeneity 
was first detected in EGF binding kinetic experiments in cells, as these display characteristic 
concave-up Scatchard plots (Magun et al. 1980; Shoyab et al. 1979). As HER1 is expressed as 
a single translation product (Ullrich & Schlessinger 1990), the concave-up EGF-binding 
Scatchard plots were interpreted as indicating the presence of two receptor populations: a 
small minority of high-affinity receptors with dissociation constants (KD) of <1 nM that 
mediate most signalling events, and a majority of low affinity receptors with KD of >1 nM 
(Defize et al. 1989; Friedman et al. 1984). When crystallographic structural data became 
available ~ 10 years ago, the high- and low-affinity populations were initially expected to be 
extended HER1 dimers and tethered HER1 monomers, respectively; however, in this model 
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stabilization of the extended dimer configuration by one ligand molecule would facilitate 
the binding of a second ligand to the remaining unliganded receptor in the dimer, resulting 
in positive cooperativity and therefore concave-down Scatchard plots (Mattoon et al. 2004). 
Using global modelling of ligand-binding data as a function of receptor number, Macdonald 
and Pike subsequently showed that EGF-binding heterogeneity could be accounted for by 
negative cooperativity in HER1 dimers (Macdonald & Pike 2008). However, negative 
cooperativity requires that ligand binding to one subunit of the HER1 dimer decreases the 
ligand affinity of the other subunit. This would, in turn, require the interactions between 
ligand and the two subunits of the receptor dimer to be asymmetric, inconsistent with the 
symmetry observed in the back-to-back structure of HER1. A series of recent 
crystallographic structures recently showed that in the drosophila counterpart of HER1 
(known as drosophila EGFR or dEGFR) the extracellular domain asymmetry is induced by 
the binding of the first ligand growth factor to the dEGFR dimer, which structurally 
restrains the unoccupied binding site, reducing the affinity for binding of the second ligand 
(Alvarado et al. 2010). Interestingly, concave-up Scatchard plots were observed in 
preparations of the isolated extracellular region of the dEGFR, in direct contrast with its 
human counterpart, in which concave-up plots are observed only when ligands bind to full-
length receptors in cells. These differences suggest that other receptor regions, 
conformations, and/or other unknown cellular components must be involved in the 
regulation of ligand affinity in HER1 in the cellular environment. A better understanding of 
the conformation of HER1 in the plasma membrane environment is therefore required to 
understand the origin of the heterogeneity of EGF-binding. 
11. Using FRET microscopy to report in situ protein conformation 
Besides ligand-ligand interactions, FRET can also be employed to investigate the 
conformation of proteins at the plasma membrane, for example by measuring the distance 
from a specific site in the protein of interest (e.g. the binding site of a growth factor 
ligand) to the cell surface (Fig. 5). Protein-membrane distances can be determined from 
the variation of the efficiency of FRET between fluorescent donors attached to the protein 
of interest and acceptors labelling the cell surface, measured as a function of acceptor 
surface density (Fig. 5). When crystal structures of the protein and/or protein fragments 
are available, protein-membrane distances derived from FRET can be used to constrain 
the disposition of protein structures with respect to the plasma membrane to inform on 
protein conformation in situ.  
Analytical expressions describing the energy transfer process between random distributions 
of donors (e.g. in specific sites in proteins) and acceptors on lipid membrane surfaces have 
been derived for a number of geometries (see for example Wolber & Hudson 1979). The 
solutions to these equations are the distance of closest approach between the protein-bound 
fluorescent donor probe and a lipid acceptor chromophore at the plasma membrane. 
Examples using this FRET method include an investigation to derive the mean distance 
between the EGF binding site of HER1 and the plasma membrane of cells in suspension 
(Carraway et al. 1990), changes in conformation of 4-Integrin during activation (Chigaev et 
al. 2003), and the minimum separation between the protein portion of GPI-anchored 
proteins to the bilayer surface (Lehto & Sharom 2002).  
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Fig. 5. A cartoon illustrating the FRET problem in two dimensions. Two receptor dimers are 
depicted bound to donor-labelled EGF (green spheres). The plasma membrane is labelled 
with lipid acceptors (red). Many distances are possible between each donor and the 
acceptors in the membrane. By varying the concentration of acceptors at the plasma 
membrane the vertical distance from donors to the cell surface can be calculated (Tynan et 
al. 2011). 
The three examples cited were derived from cell-averaged steady-state intensity 
measurements (e.g., flow cytometry). The efficiency of FRET between a random distribution 
of donors and acceptors can also be determined using fluorescence lifetime imaging 
microscopy (FLIM). This method images with optical resolution the shortening of the 
fluorescence decay time of donor-labelled EGF induced by the lipid acceptors. Being a time-
resolved assay, FLIM has the advantage of being able to directly measure the time between 
the absorption and emission of individual photons in the FRET donor fluorophores, 
providing results largely free from artefacts such as photobleaching and radiative transfer 
which can increase the errors in the measurement (Martin-Fernandez et al. 2002).  
Using the combination of FLIM and FRET to measure protein-membrane distances, Webb et 
al obtained initial evidence for two types of EGF/HER1 complexes, tilted and upright with 
respect to the cell surface, that are associated to high-affinity and low-affinity EGF binding, 
respectively (Webb, et al. 2008). Subsequently, using MD simulations Kästner et al. showed 
that, with minor rearrangements, the HER1 back-to-back dimer can be aligned almost flat on 
the cell membrane, leading to conformational changes which further stabilize the 
extracellular dimer (Kästner et al. 2009). This work also showed that alignment on the cell 
surface and the interactions between the HER1 dimer and the upper leaflet of the membrane 
that follow break the pseudo-2-fold symmetry of the HER1 extracellular region, resulting in 
a highly asymmetric HER1 dimer structure. 
12. HER1 can adopt key features of dEGFR asymmetry 
To investigate the relevance of the MD-derived asymmetric model of the HER1 dimer 
relaxed on the membrane (Kastner et al. 2009) to EGF-binding heterogeneity and negative 
cooperativity (Macdonald & Pike 2008)), Tynan et al extended the FLIM-FRET assay 
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previously reported (Webb et al. 2008) to include FRET titrations as a function of acceptor 
concentration together with a data analysis method based on Monte-Carlo simulations 
(Tynan et al. 2011). This method allowed full quantification of the distance of closest 
approach between HER1-bound ligands and the surface of adherent epithelial cells, the 
assessment of the variation associated to the distance measurement, and also the rejection of 
potential sources of artifacts resulting from non-uniform distributions of FRET donors and 
acceptors.  
Given the known flexibility regions in the accepted crystallographic HER1 ectodomain 
dimer structure, the FRET-derived distance data obtained from HER1 that display high-
affinity for EGF (< 4 nm) could only be reconciled with HER1 structural data if receptors are 
aligned flat on the membrane (Fig. 6). MD simulations of doubly-liganded, singly-liganded 
and unliganded HER1 dimers aligned on a model membrane under the same conditions 
revealed that the asymmetry resulting from alignment on the membrane shares a number of 
key features with the equivalent doubly-liganded and singly-liganded structures observed 
recently in soluble dEGFR (Alvarado et al. 2010). These results suggest that the structural 
basis for negative cooperativity is conserved from invertebrates to humans but that in HER1 
the extracellular region asymmetry requires interactions with the plasma membrane. 
 
Fig. 6. The EGFR ectodomain dimer with two bound ligands, modelled on crystallographic 
structures (Garret et al. 2002; Ogiso et al. 2002; Ferguson et al. 2003) and placed in the 
membrane. Darker green spheres indicate the N termini of the ligands to which donor dyes 
are attached. Configurations standing upright and lying down are compared. 
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13. Imaging membrane protein interactions at the nanoscale 
Understanding the structure-function relationships of biological macromolecules ultimately 
requires us to determine molecular structure at a range of resolutions. These include: 
Atomic resolutions (~1 Å) for detailed protein structure, derived from x-ray crystallography 
(Vrielink & Sampson 2003); 1-10 nm for measurement of conformations and inter-molecular 
distances, a range covered by electron microscopy (Agronskaia et al. 2008) and FRET (Stryer 
& Haugland 1967); and 10-20 nm for measurement of inter-unit separation and therefore the 
oligomerisation states of protein complexes. Given the importance of HER homo and hetero-
oligomerisation in signalling, access to distances in the 10-20 nm range is crucial in 
investigation of HER interactions because, as discussed above, structural studies indicate 
that the inter-unit separation in the preferred receptor dimer should be in the region of 10-15 
nm (Fig. 3) (Garrett et al. 2002; Ogiso et al. 2002). However, measurements in this range are 
challenging because these distances fall in a “resolution gap” between FRET and optical 
microscopy, which is diffraction-limited around 200 nm at best.  
In recent years, a number of so-called “super-resolution” optical methods have been 
developed, that break the diffraction limit for light microscopy. These include stimulated 
emission depletion (STED) microscopy (Hell 2003) near-field scanning optical microscopy 
(NSOM) (Dunn 1999), photo-activated localization microscopy (PALM) (Betzig et al. 2006), 
fluorescence imaging with one-nanometre accuracy (FIONA) (Yildiz & Selvin 2005), single-
molecule high resolution imaging with photobleaching (SHRImP) (Balci et al. 2005), 
nanometre-localized multiple single-molecule (NALMS) microscopy (Qu et al. 2004) and 
single-molecule high resolution co-location (SHREC) (Churchman et al. 2005). Theoretically, 
many of these techniques have the potential to measure distances in the required range. 
However, there are challenges in applying them to the cellular environment. NSOM is not 
well-suited to the wet conditions required for living or lightly fixed cells. STED and PALM 
are essentially ensemble imaging techniques that are not easily applied to the measurement 
of the distance between two or more specific molecules in the crowded cell environment. 
SHRImP, SHREC, and NALMS can measure distances between molecules with better than 
10 nm resolution. Like PALM, all these methods “beat” the diffraction limit by imaging 
single molecules, fitting the point spread function (PSF) of the microscope, and locating its 
centre with nanometre accuracy. NALMS uses single molecule detection to count discrete 
steps in traces of fluorescence intensity vs time from diffraction limited spots, each step 
corresponding to the activation or bleaching of a single fluorophore, and measuring the 
change in the PSF of the spot before and after a step. In SHRImP, global fitting is carried out 
on spots before and after bleaching, producing nearly identical results to the sequential 
NALMS method. SHREC again uses PSF fitting, but two different fluorophores with 
different spectral characteristics are used, imaged in distinct channels which must be very 
accurately registered to determine intra-molecular distance. In all these techniques, spatial 
resolution is ultimately limited by the signal-to-noise ratio of the data, which determines the 
precision with which the centre of the PSF can be determined. For this reason, SHRImP, 
SHREC, and NALMS have so far been demonstrated only in “clean” samples such as 
purified, immobilised molecules on glass, and in the presence of antifade reagents. 
The environment of mammalian cells is not conducive to the collection of high signal-to-
noise data. The main source of background noise is intracellular autofluorescence, arising 
from molecules such as NADPH and flavins (Monici 2005). A common approach to reduce 
www.intechopen.com
Investigating the Conformation of HER Membrane  
Proteins in Cells via Single Molecule and FLIM Microscopy  
 
85 
background when looking at membrane proteins is to use total internal reflection (TIRF) 
excitation (Fig. 1) (Axelrod 1989). TIRF creates an evanescent field on the coverslip on which 
the cells are cultured. The field reduces exponentially with depth, and only penetrates 
approximately 300 nm into the sample. Thus, fluorescence is not excited in the bulk of the 
cell, reducing autofluorescence. This enables single molecule detection, as shown in Fig. 7 
(left panel). Single molecules are clearly visible, but there is also a contribution from 
background noise. This results from residual autofluorescence, scattered light, and 
fluorescence from out-of-focus fluorophores.  
In our laboratory we are developing new methods to improve the accuracy of intra-
molecular distance measurement in cells and tissues. We currently achieve sub-10 nm 
positioning resolution in cells by using new data fitting algorithms that perform well in the 
noisy environment of cells (manuscript in preparation). Crucially, our techniques give 
robust estimates of errors, allowing the significance of distance measurements to be 
properly determined. Fig. 7 (right panel) shows typical single molecule traces and 
accompanying position measurement from labelled HER1 complexes in fixed epithelial 
cervical carcinoma HeLa cells. 
   
Fig. 7. Left: Single molecule TIRF image of EGFR in the plasma membrane of HeLa cells. 
EGFR are labelled with their ligand EGF, conjugated with the fluorophore Atto 647N (bar 8 
µm). Right: Traces of single molecule fluorescence intensity (red) vs time for two example 
spots in fixed HeLa cells labelled with EGF-Atto 647N. a) shows a relatively short intra-
molecular distance, b) a longer distance. Fluorophore x and y positions are plotted in black 
and blue, respectively. 
14. Determining dynamic interactions from diffusion at the membrane 
HER molecules interact with each other and with other network proteins while being 
embedded in the lipid bilayer of the plasma membrane, which is composed of neutral, 
charged, saturated and unsaturated lipids (Fig. 1). The lipids in the membrane consist of a 
hydrophilic charged region, the phospholipids heads, which form the extreme outer and 
inner leaflets of the membrane, and hydrophobic C-H chains of different lengths (typically 
from C12 to C20) that forms the core of the bilayer (van Meer 2005). Water molecules 
concentrate on the inner and outer surfaces of the plasma membrane at the boundaries with 
the extracellular and intracellular regions and can occasionally enter the bilayer through 
www.intechopen.com
 Molecular Imaging 
 
86
surface defects created by lipid mismatch. Hydrophilic protein regions are excluded from 
the hydrophobic inner part of the lipid bilayer and stick out from the plasma membrane. 
The simplest membrane model consists of a 2-D liquid model surrounded by a 3-D solvent 
(Singer & Nicolson 1972). In this simple model, membrane proteins diffuse freely in the lipid 
bilayer which is modelled as a viscous liquid. Proteins interact with the surrounding lipid 2-
D ‘liquid’ and diffuse with a speed that depends on lipid viscosity. However, it is observed 
experimentally that the lateral mobility of proteins in biological membranes can be orders of 
magnitude slower than in synthetic membranes. Reasons for this include: 
i. The presence of lipid rafts: The plasma membrane is composed of different lipids (e.g. 
phospholipids, sphingolipids and cholesterol) that can form microdomains of different 
viscosity. These rafts microdomains concentrate certain proteins (including HER 
molecules) and exclude others (see for example (Kusumi et al. 2005; Nagy et al. 2002). 
ii. Intra-membrane barriers: Biological membranes are quite crowded with 15-35% of 
surface area occupied by many different types of proteins which can interact with each 
other affecting diffusion mobility (Scheuring & Sturgis 2005). 
iii. Skeletal interactions: Proteins are able to interact with protein scaffolds and the 
cytoskeletal network beneath the plasma membrane in the intracellular side, which 
have the effect of corralling the membrane proteins in some regions and not others 
(reviewed in Costa et al. 2011).  
 
Fig. 8. Two-colour single molecule tracking of T47D cells. a) White light transmission image; 
b) cells labelled with 0.1 nM anti-ErbB2 affibody-Atto 647N; c) cells labelled with 2 nM anti-
EGFR affibody-Alexa 488; d and e) single molecule tracks (green) from the spots located 
within the boxes marked in b and c. 
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The role of membrane microdomains, intra-membrane barriers and skeletal interactions in 
HER signalling is not yet understood. This role can be investigated using single molecule 
tracking. Advantages of a single molecule approach include the ability to observe dynamic, 
stochastic behaviour, such as compartmentalized diffusion (Andrews et al. 2008; Dahan et 
al. 2003; Fujiwara et al. 2002) that would be masked in ensemble measurements, and the 
ability for localisation of molecules with a precision well below the diffraction limit of light 
(see section 11).  
To investigate protein diffusion and protein-membrane interaction in the HER bio-system 
we have used, for example, a two colour tracking system (Clarke et al. 2011) to follow the 
movements of HER1 and HER2 at the plasma membrane of live T47D cells, a human ductal 
breast epithelial tumour cell line cell model that expresses the four HER receptor types at a 
level between 10,000-30,000 receptors per cell. Fig. 8 shows single molecule images of HER1, 
and HER2 in living cells in their basal state. The receptors are labelled with an anti-HER1 
affibody (Nordberg et al. 2010) conjugated with Alexa 488 an anti-HER2 affibody (Tran et al. 
2007) conjugated with Atto 647N. The data were analysed using Bayesian segmentation 
algorithms and other data analysis methods described in (Rolfe et al. 2011). The resulting 
tracks indicate that HER1 displays in these cells higher mobility at the plasma membrane 
than HER2. We are now developing the methods to extract from these data the different 
mean displacements of each receptor in the plasma membrane from which their co-
localisation kinetics can be derived.  
 
Fig. 9. Experimental and computational methods to investigate the HER signalling network 
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15. Towards an integrated approach  
Ultimately, our goal is to use a cross-disciplinary portfolio of experimental and data analysis 
techniques to describe the HER signalling network not just in cell models but also in the real 
world setting. To achieve this we aim at deriving models of ligand-induced behaviour 
exploiting combined single molecule imaging, ensemble FLIM analysis and systems 
predictions. We also aim at establishing how HER signalling is influenced by feed-back 
loops and internal and external perturbations, e.g. HER mutations (seen in human subjects), 
RTK inhibitors and function-blocking antibodies. We also plan to combine experimental 
approaches with molecular dynamics and coarse-grained simulations and to explore data 
mining techniques for exploiting this rich data (Fig. 9). 
16. View to the future: Potential clinical applications and take home message 
We ultimately aim to refine single molecule fluorescence detection to be applicable to 
human tissues. We have already demonstrated single-molecule fluorescence imaging of 
HER receptors in fixed and frozen tissue sections from mouse tumour xenografts and 
human tissue biopsies (manuscript in preparation). This work is being done in collaboration 
with Prof. Peter Parker and colleagues at King’s College London/Guy’s & St Thomas’ NHS 
Foundation Trust. Our aim is to extend the use of fluorescently labelled ligands, affibodies, 
anti-HER monoclonal antibodies (mAbs) and function blocking antibodies from cultured 
cell models to investigations of HER signalling on normal primary cells and tissue sections. 
We also plan to study naturally occurring somatic mutations (e.g. in human lung 
adenocarcinoma, see review on HER1 mutations in: Lynch et al. 2004) and also study cross-
talk interactions with other non-HER receptors in lung and breast cancer tissue. It is hoped 
that these experiments will allow us to obtain further insights into the HER network and 
assess predictions made by our models. Once the methods have been optimised, studies will 
be extended to include other carcinoma cells and tissues, including matched normal tissue. 
Downstream targets of receptor activation will be assessed by western blotting to set the 
baseline population behaviour and ensure specificity of reagents. It is hoped that results 
from these experiments will provide novel insight on how the HER network operates at the 
tissue level and the supra-molecular rules and controls that are necessary to ensure normal 
network function. 
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